12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BCX5191: IND withdrawn

BioCryst withdrew an IND for BCX5191 after FDA expressed concerns about the HCV candidate's preclinical toxicity profile. According to the company, the agency is concerned that exposure levels of BCX5191 that will be necessary to reduce viral load in humans will be toxic. The company plans...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >